Our Platform

UNIQUE PLANT-BASED PLATFORM WITH THE POTENTIAL TO TRANSFORM DRUG DEVELOPMENT

KBio’s plant-based platform has the ability to produce novel antibody and vaccine candidates with high purity at a fraction of the time and cost of current technologies. The speed and efficiency demonstrated by the KBio platform has the potential to enhance and expand antibody research & development, particularly in areas that have previously had very limited targeted treatment options. Using the platform, KBio can create monoclonal antibodies faster than current technologies, leveraging the rapid speed and lower upfront costs of producing new monoclonal antibodies.i We are also exploring new models of pandemic preparedness and response that could enable and enhance future production of antibodies, vaccines, and other biologics.

Click Through
To Learn Our Process

VectorBuilding
PlantGrowth
Infiltration
Expression
Extraction
DrugRelease

~ 3 – 4 weeks

(rare infection)

~ 1 week

~ 1 week

Unique features of the Plant-Based Platform to enhance future R&D activities:

1


Speed

‘Plug & play’ approach to design*, development, and production of cGMP biologics within a ~6-8-week period

2


Robust & Flexible

Ability to reproduce wide range of mAbs. With potential to produce other mAbs and vaccine antigens

3


Safe & Tolerable

demonstrated in multiple human clinical studies of candidate mAbs and vaccinesi

4


Scalable

Potential for high-volume production; ease of tech transfer globally

5


Regulatory

Three active INDs for investigational mAb products and for two investigational vaccines

6


Thermostable+

Room-temperature stability

7


Mucosal Delivery+

Mucosal delivery found to be effective across multiple respiratory pathogens

In addition, the platform can be used to produce ‘small-scale’ batches of biological treatments, not possible with the current mammalian cell approach. This can support and enable the production of biological material for pharm/tox and clinical studies in around 3 months for as little as $1M, enabling a “fast-to-fail” strategy.

* ‘Plug & Play’ approach only applies to mAbs
+ For our TMV-conjugated vaccines only
i Swope K, Morton J, Pogue GP, Hume S, Pauly M H, Shepherd J, C A, Barry Bratcher 2, Whaley K, Zeitlin L, Davis K, Haydon H. Manufacturing plant-made monoclonal antibodies for research or therapeutic applications. Methods Enzymol. 2021;660:239-263. DOI: 10.1016/bs.mie.2021.05.011